Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells

Yayun Liang,1,2,* Sandy Goyette,1,2,* Salman M Hyder1,2 1Department of Biomedical Sciences, 2Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, USA *These authors contributed equally to this work Abstract: Clinical trials and studies have shown that postmenopausal women und...

Повний опис

Бібліографічні деталі
Автори: Liang Y, Goyette S, Hyder SM
Формат: Стаття
Мова:English
Опубліковано: Dove Medical Press 2017-07-01
Серія:Breast Cancer: Targets and Therapy
Предмети:
Онлайн доступ:https://www.dovepress.com/cholesterol-biosynthesis-inhibitor-ro-48-8071-reduces-progesterone-rec-peer-reviewed-article-BCTT
_version_ 1831570459643084800
author Liang Y
Goyette S
Hyder SM
author_facet Liang Y
Goyette S
Hyder SM
author_sort Liang Y
collection DOAJ
description Yayun Liang,1,2,* Sandy Goyette,1,2,* Salman M Hyder1,2 1Department of Biomedical Sciences, 2Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, USA *These authors contributed equally to this work Abstract: Clinical trials and studies have shown that postmenopausal women undergoing combination hormone replacement therapy containing estrogen and progestin have an increased risk of breast cancer compared with women taking estrogen or placebo alone. Using animal models, we have previously shown that synthetic progestins, including medroxyprogesterone acetate (MPA), which is widely used clinically, accelerate breast cancer tumor growth and promote metastasis. Furthermore, we have found that MPA elevates CD44 protein expression and aldehyde dehydrogenase (ALDH) activity, two markers of cancer stem cells (CSCs), and increases mammosphere formation, another hallmark of stem cells, in hormone-dependent T47-D human breast cancer cells. Herein, we show that RO 48-8071 (RO), an inhibitor of cholesterol synthesis, reduced MPA-induced CD44 protein expression in two hormone-dependent human breast cancer cell lines, T47-D and BT-474. Because we have previously shown that MPA induction of CD44 is progesterone receptor (PR) dependent, we examined RO’s effects on PR protein and mRNA expressions in T47-D cells. PR mRNA levels remained unchanged after RO treatment; however, RO significantly reduced the protein expression of both PR receptor isoforms, PR-A and PR-B. Using the proteasome inhibitor MG-132, we demonstrated that RO decreases PR protein expression in T47-D cells via the proteasomal degradation pathway. Importantly, treatment of T47-D cells with RO abolished MPA-induced mammosphere formation. Based on our observations, we contend that RO may represent a novel means of preventing MPA-induced CSC expansion. RO could be used clinically to both treat and prevent hormone-dependent breast cancers, which represent the majority of human breast cancers. RO may also have clinical utility in reducing resistance to antihormone therapy. Keywords: breast cancer, cholesterol biosynthesis inhibitor, RO 48-8071, medroxyprogesterone acetate, cancer stem cells, CD44
first_indexed 2024-12-17T12:51:39Z
format Article
id doaj.art-c98d10a822224ac5a21c01c20a68c5d7
institution Directory Open Access Journal
issn 1179-1314
language English
last_indexed 2024-12-17T12:51:39Z
publishDate 2017-07-01
publisher Dove Medical Press
record_format Article
series Breast Cancer: Targets and Therapy
spelling doaj.art-c98d10a822224ac5a21c01c20a68c5d72022-12-21T21:47:35ZengDove Medical PressBreast Cancer: Targets and Therapy1179-13142017-07-01Volume 948749433655Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cellsLiang YGoyette SHyder SMYayun Liang,1,2,* Sandy Goyette,1,2,* Salman M Hyder1,2 1Department of Biomedical Sciences, 2Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, USA *These authors contributed equally to this work Abstract: Clinical trials and studies have shown that postmenopausal women undergoing combination hormone replacement therapy containing estrogen and progestin have an increased risk of breast cancer compared with women taking estrogen or placebo alone. Using animal models, we have previously shown that synthetic progestins, including medroxyprogesterone acetate (MPA), which is widely used clinically, accelerate breast cancer tumor growth and promote metastasis. Furthermore, we have found that MPA elevates CD44 protein expression and aldehyde dehydrogenase (ALDH) activity, two markers of cancer stem cells (CSCs), and increases mammosphere formation, another hallmark of stem cells, in hormone-dependent T47-D human breast cancer cells. Herein, we show that RO 48-8071 (RO), an inhibitor of cholesterol synthesis, reduced MPA-induced CD44 protein expression in two hormone-dependent human breast cancer cell lines, T47-D and BT-474. Because we have previously shown that MPA induction of CD44 is progesterone receptor (PR) dependent, we examined RO’s effects on PR protein and mRNA expressions in T47-D cells. PR mRNA levels remained unchanged after RO treatment; however, RO significantly reduced the protein expression of both PR receptor isoforms, PR-A and PR-B. Using the proteasome inhibitor MG-132, we demonstrated that RO decreases PR protein expression in T47-D cells via the proteasomal degradation pathway. Importantly, treatment of T47-D cells with RO abolished MPA-induced mammosphere formation. Based on our observations, we contend that RO may represent a novel means of preventing MPA-induced CSC expansion. RO could be used clinically to both treat and prevent hormone-dependent breast cancers, which represent the majority of human breast cancers. RO may also have clinical utility in reducing resistance to antihormone therapy. Keywords: breast cancer, cholesterol biosynthesis inhibitor, RO 48-8071, medroxyprogesterone acetate, cancer stem cells, CD44https://www.dovepress.com/cholesterol-biosynthesis-inhibitor-ro-48-8071-reduces-progesterone-rec-peer-reviewed-article-BCTTbreast cancercholesterol biosynthesis inhibitorRO 48-8071medroxyprogesterone acetatecancer stem cellsCD44
spellingShingle Liang Y
Goyette S
Hyder SM
Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells
Breast Cancer: Targets and Therapy
breast cancer
cholesterol biosynthesis inhibitor
RO 48-8071
medroxyprogesterone acetate
cancer stem cells
CD44
title Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells
title_full Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells
title_fullStr Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells
title_full_unstemmed Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells
title_short Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells
title_sort cholesterol biosynthesis inhibitor ro 48 8071 reduces progesterone receptor expression and inhibits progestin dependent stem cell like cell growth in hormone dependent human breast cancer cells
topic breast cancer
cholesterol biosynthesis inhibitor
RO 48-8071
medroxyprogesterone acetate
cancer stem cells
CD44
url https://www.dovepress.com/cholesterol-biosynthesis-inhibitor-ro-48-8071-reduces-progesterone-rec-peer-reviewed-article-BCTT
work_keys_str_mv AT liangy cholesterolbiosynthesisinhibitorro488071reducesprogesteronereceptorexpressionandinhibitsprogestindependentstemcelllikecellgrowthinhormonedependenthumanbreastcancercells
AT goyettes cholesterolbiosynthesisinhibitorro488071reducesprogesteronereceptorexpressionandinhibitsprogestindependentstemcelllikecellgrowthinhormonedependenthumanbreastcancercells
AT hydersm cholesterolbiosynthesisinhibitorro488071reducesprogesteronereceptorexpressionandinhibitsprogestindependentstemcelllikecellgrowthinhormonedependenthumanbreastcancercells